News

June 21, 2017

Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego
INDIANAPOLIS, June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neuro...

June 9, 2017

IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention
BRUSSELS and INDIANAPOLIS, June 9, 2017 /PRNewswire/ -- More than 400 million people are living with diabetes. In a further effort to help spread lessons learned from clinical research to benefit people affected by this condition, the International Diabetes Federation (IDF) and Eli Lilly and Company (NYSE: LLY) have come together for the second pha...

June 8, 2017

Lilly Announces Strategic Collaboration with KeyBioscience AG
STANS, Switzerland and INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and KeyBioscience AG have agreed to a new collaboration focused on the development of Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for metabolic disorders such as type 2 diabetes, the companies announced toda...

June 1, 2017

Derica Rice to Retire as Lilly Chief Financial Officer
INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Derica Rice, executive vice president global services and chief financial officer, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of Lilly's executive committee. ...

May 10, 2017

Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications
INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Leigh Ann Pusey will be joining Lilly as senior vice president of corporate affairs and communications, effective June 12, 2017. She will be a member of Lilly's executive committee reporting directly to president and chief executive officer, David A. R...

April 4, 2017

Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students
INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, ...

March 24, 2017

Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017
INDIANAPOLIS, March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas. The investments are being driven...

March 2, 2017

Lilly Announces Changes in Senior Management
INDIANAPOLIS, March 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Qualit...

March 1, 2017

Lilly Completes Acquisition of CoLucid Pharmaceuticals
INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As...

February 9, 2017

Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors
INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the...

February 2, 2017

Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents
INDIANAPOLIS, Feb. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In the fourth quarter of 2015, the Japan P...

January 18, 2017

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migra...

January 12, 2017

U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent
INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the ca...

January 5, 2017

Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities
INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said, "Lilly begins 2017 with a clear vie...

January 3, 2017

Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio
GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site and several pipeline asse...

Showing 1-15 of 15 Page: 1